Dual GLP1 and GIP agonistic behavior define tirzepatide. It is now employed as a secondary diabetic treatment and given as a onceweekly subcutaneous injection, same as other GLP1 drugs.

A glucosedependent insulinotropic polypeptide (GIP) receptor agonist, tirzepatide also acts on the glucagonlike peptide1 (GLP1) receptor. It is not authorized to treat type 1 diabetes mellitus and has not been tested on those with pancreatitis. Implemented as a second-line protection against type 2 diabetes, this GIP and GLP1 receptor agonist lowers body weight significantly.

Recent clinical trials show tirzepatide lowers hemoglobin A1C levels more effectively than a placebo. Hemoglobin A1C When Tirzepatide was ingested at the maximum dose of 15 mg per week, it decreased by 2.34%. A 40 week period showed this to be true. A well-known GLP1 medication prescribed for weight reduction treatment is comparable to this dosedependent connection with weight loss.

Tirzepatide has been shown to work more effectively than GLP1 medications but same. Its capacity to aid weight loss and lack of liver toxicity would secondarily benefit those with nonalcoholic fatty liver disease (NAFLD).

Acting as an agonist for both the glucagonlike peptide1 (GLP1) and gastric inhibitory polypeptide (GIP) receptors, Tirzepatide is a synthetic peptide. Having 39 amino acids, it is a gastric inhibitory polypeptide mimetic. Functionally, it stimulates the pancreas to produce more insulin, thereby reducing blood glucose levels. Similarly elevated by tirzepatide are adiponectin levels. With its dual agonism capability, it lowers hyperglycaemia dramatically compared to GLP1 agonist medicines taken alone. Hunger is reduced as well.

In rats, tirzepatide encourages thyroid Ccell malignancies.

For those with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) or a family or personal history of MTC, tirzepatide is not suitable.

For individuals with hepatic impairment, no tirzepatide dosage modification is advised.

Patients with Renal Impairment: Tirzepatide is linked to gastrointestinal ADRs that include nausea, vomiting, diarrhea leading in dehydration and therefore causing acute kidney injury. In people prone to dehydration, use with caution.

In vitro experiments have shown tirzepatide to have little promise for inhibiting drug transporters or to suppress or induce CYP enzymes.

Gastric emptying was most influenced by a single dose of 5 mg tirzepatide; it slowly diminished afterwards.

Coadministration at week 4 did not greatly change acetaminophen Cmax and tmax; but, total acetaminophen exposure (AUC024hr) stayed same.

What to Know About Side Effects

Most people using this medication don’t experience serious side effects. The most common issues tend to be related to the stomach and digestion, but other side effects can happen too, though less often.

Stomach and Digestion

• Many people notice a reduced appetite, which might help explain some intentional weight loss.
• Up to 1 in 10 people may feel nauseous or have diarrhea.
• Some might also experience vomiting, acid reflux, or constipation.
• Because this medicine can slow down how fast the stomach empties, it might make it harder for other oral medications to be absorbed properly. This is especially important for people who already have slow digestion.
• For example, birth control pills taken by mouth may not work as well, so it’s a good idea to use other forms of contraception.

Heart

• Some people might develop a faster heartbeat (sinus tachycardia), but this can often be managed with other medications.

Kidneys

• Rarely, kidney problems can happen, usually because of dehydration from vomiting or diarrhea.
• This can affect both healthy people and those with existing kidney issues.
• It’s important to watch for signs of dehydration, like feeling very thirsty or dizzy, to protect kidney health.

Skin and Injection Site

• Occasionally, some people have allergic reactions or irritation where the medicine is injected.
• These reactions are uncommon and similar to what’s seen with related medications.
• If this happens, talk to your doctor—they might suggest stopping the medication.

Pancreas

• There’s a known risk of inflammation of the pancreas (pancreatitis) with this type of medication.
• If you experience severe belly pain, it’s important to get emergency medical help right away.
• Some people might have higher levels of certain enzymes related to the pancreas without symptoms.

Gallbladder

• Some patients have developed gallstones or inflammation of the gallbladder while on this medication.

Eyes

• If you have diabetic eye problems, your symptoms might temporarily get worse if your blood sugar improves quickly.
• Any changes in vision should be reported to your doctor immediately.

Blood Sugar and Hormones

• There’s a small chance of low blood sugar (hypoglycemia), especially if you’re also taking insulin or certain diabetes pills.
• It’s important to know the signs of low blood sugar, like shakiness, sweating, or confusion, and to talk to your doctor about how to manage it.

The dearth of data on tirzepatide use during pregnancy makes it impossible to assess the medication’s possible connection with birth abnormalities and adverse maternal or fetal outcomes. Poorly controlled gestational diabetes has been connected with a greater risk to the mother and unborn child. Research on animal reproduction also reveals higher rates of skeletal, visceral, and external defects. Tirzepatide exposure during pregnancy could thus present risks for the developing baby.

Therefore, tirzepatide should only be taken when pregnant if the benefit outweighs the risk to the developing baby. After thorough assessment for potential teratogenic effects, tiropezatide should only be given to women of childbearing age. Doctors should also discuss beginning a contraception plan before suggesting tirzepatide. Moreover, the effectiveness of oral hormonal birth control declines while using tirzepatide medicine.
Barrier contraception should be used for at least four weeks after the commencement of tirzepatide treatment or shared decisionmaking may be needed to switch to a nonoral method of birth control.

Tirzepatide’s presence in human or animal milk is not known, thus its impact on a nursing baby is also unknown.

Tirzepatide is a massive, high molecular weight molecule.

Upon receipt of medication, immediately store between 35°F to 46°F (2°C – 8°C). Keep all medicines out of the reach of children. Throw away any unused medicine within 28 days of puncture or the BUD, whichever comes first. Do not flush unused medications or pour them down a sink or drain.

1. Farzam K, Patel P. Tirzepatide. [Updated 2023 May 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK585056/– LinkOpens in New Tab
2. Tirzepatide for type 2 diabetes.Med Lett Drugs Ther.2022 Jul 11;64(1654):105-107. https://pubmed.ncbi.nlm.nih.gov/35802842/– LinkOpens in New Tab
3. Collins L, Costello RA. StatPearls [Internet].StatPearls Publishing; Treasure Island (FL): Jan 13, 2023. Glucagon-like Peptide-1 Receptor Agonists. https://pubmed.ncbi.nlm.nih.gov/31855395/– LinkOpens in New Tab
4. Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, Rodríguez Á. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022 Feb 08;327(6):534-545. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8826179/– LinkOpens in New Tab
5. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): Jun 20, 2022. Tirzepatide.
6. Sun B, Willard FS, Feng D, Alsina-Fernandez J, Chen Q, Vieth M, Ho JD, Showalter AD, Stutsman C, Ding L, Suter TM, Dunbar JD, Carpenter JW, Mohammed FA, Aihara E, Brown RA, Bueno AB, Emmerson PJ, Moyers JS, Kobilka TS, Coghlan MP, Kobilka BK, Sloop KW. Structural determinants of dual incretin receptor agonism by tirzepatide. Proc Natl Acad Sci U S A. 2022 Mar 29;119(13):e2116506119. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9060465/– LinkOpens in New Tab
7. Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Jun 20, 2022. Tirzepatide. https://pubmed.ncbi.nlm.nih.gov/35759552– LinkOpens in New Tab
8. Trujillo J. Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes. J Clin Pharm Ther. 2020 Sep;45 Suppl 1(Suppl 1):43-60. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540535/– LinkOpens in New Tab
9. Bethel MA, Diaz R, Castellana N, Bhattacharya I, Gerstein HC, Lakshmanan MC. HbA1c Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression. Diabetes Care. 2021 Jan;44(1):290-296. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783944/– LinkOpens in New Tab
10. Chavda VP, Ajabiya J, Teli D, Bojarska J, Apostolopoulos V. Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. Molecules. 2022 Jul 05;27(13) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9268041/